Avelas Biosciences is a San Diego-based biotechnology company focused on developing fluorescent technologies that advance a new standard-of-care for cancer surgery. Its lead candidate, AVB-620, is expected to enter clinical studies in 2014. Avelas was founded by Avalon Ventures on technology from Nobel Prize winner Roger Y. Tsien, Ph.D.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/12 | $7,650,000 | Series A |
Avalon Ventures | undisclosed |
| 09/10/14 | $7,400,000 | Series B |
Avalon Ventures WuXi PharmaTech | undisclosed |
| 08/18/16 | $20,000,000 | Series C |
Alexandria Venture Investments Avalon Ventures Bregua Corporation Ervington Investments Pharmstandard International WuXi Healthcare Ventures | undisclosed |
